Which Drugs Are Covered The three GLP-1 medications covered under the Bridge are: Wegovy (semaglutide) all approved formulations Zepbound (tirzepatide) KwikPen formulation only (the single-dose vial and single-dose pen formulations of Zepbound are excluded) Foundayo (orforglipron) the oral GLP-1 option, all formulations All three are available at the $50 monthly copay for eligible enrollees
The guidance below is based on injectable Wegovy requirements (same FDA indication and active ingredient), but individual insurer handling may evolve as the product matures
The multi-receptor approach of retatrutide demonstrates enhanced metabolic benefits across multiple pathways
Why Customers Love It: Clean, natural formulation Non-invasive Vegan, gluten-free, and sugar-free Designed and distributed in Canada Feel balanced
Rotate injection sites weekly to prevent lipohypertrophylocalized thickening of fatty tissue from repeated injections in the same spot
By calming exaggerated reward signals, GLP-1 drugs may reduce the pull of alcohol, nicotine, sugar, and possibly other substances